secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senseonics Holdings, Inc. (SENS)
CIK:        0001616543
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001104659-26-002736
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senseonics Q4 2025 preliminary revenue $14.2M (+71% YoY); FY2025 $35.2M; guides FY2026 $58-62M
--------------------------------------------------------------------------------

- Preliminary Q4 2025 revenue $14.2M (+71% YoY); FY2025 revenue $35.2M (+57% YoY); cash $94.3M.
- Patient base grew 103% in Q4 2025 vs Q4 2024; largest new patient addition in company history.
- Received FDA IDE approval to begin pivotal trial for self-powered Gemini sensor; first patients enrolled.
- 2026 revenue guidance $58-62M (65-76% growth); gross margin ~50%; commercial transition from Ascensia effective Jan 1, 2026.
- First commercial patients using pump partner Sequel's twiist insulin delivery system with Eversense 365 compatibility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1616543/000110465926002736/0001104659-26-002736-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1616543/000110465926002736/tm262845d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-002736

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer